Agoracom Blog Home

Author Archive

« Older Entries
Newer Entries »

Datametrex $DM.ca $DTMXF Announces Closing of Acquisition with Concierge Medical $WELL.ca $DOC.ca $DOCRF $VMD.ca

Posted by AGORACOM-JC at 8:38 AM on Thursday, February 11th, 2021
  • Closed its acquisition of 100% of Concierge Medical Consultants Inc.’s (“Concierge“) issued and outstanding securities (the “Transaction“), pursuant to terms of the share exchange agreement entered into between the Company, Concierge, and the shareholders of Concierge (the “Concierge Shareholders“) effective January 19, 2021 (the “Definitive Agreement“).
  • Concierge is an arm’s length private telehealth and medical concierge services

Toronto, Ontario–(February 11, 2021) –  Datametrex AI Limited (TSXV: DM) (FSE: D4G) (OTC Pink: DTMXF) (the “Company” or “Datametrex“) is pleased to announce that further to its press releases dated January 7, 2021 and January 22, 2021, it has closed its acquisition of 100% of Concierge Medical Consultants Inc.’s (“Concierge“) issued and outstanding securities (the “Transaction“), pursuant to terms of the share exchange agreement entered into between the Company, Concierge, and the shareholders of Concierge (the “Concierge Shareholders“) effective January 19, 2021 (the “Definitive Agreement“).

Concierge is an arm’s length private telehealth and medical concierge services company incorporated under the laws of British Columbia.

Terms of the Transaction

Pursuant to the Definitive Agreement, the Company issued 4,411,764 common shares in the capital of the Company (the “Common Shares“) to the Concierge Shareholders at a price of $0.17 per Common Share for an aggregate purchase price of $750,000.

No finder’s fee was payable in connection with the Transaction.

“Hospital ER’s and health practitioners’ clinics are making a strong push for patients who have mild symptoms to use telehealth platforms during the pandemic crisis to help alleviate the strain on emergency rooms and doctors’ offices and I believe this will continue after the pandemic crisis is over,” commented Dr. Jibran Sharif, MD, founder, and CEO of Concierge.

“Telemedicine visits are booming as doctors and patients have adopted social distancing amid the coronavirus crisis, and with the concierge services Dr. Sharif provide, we envision an end to end turnkey solution for patient healthcare,” said Marshall Gunter, CEO of Datametrex, with respect to the closing of the Transaction.

Operations of Concierge Upon Completion of the Transaction

Concierge has become a wholly-owned operating subsidiary of the Company. The Company has appointed Andrew Ryu, Marshall Gunter, and Dr. Jibran Sharif as the new board of the directors of Concierge, and Dr. Sharif is appointed as the President of Concierge following the closing of the Transaction (the “Closing“). In addition, concurrent with the Closing, the Company has entered into a employment agreement with the founder and President of Concierge, Dr. Jibran Sharif. In addition to his role as President of Concierge, Dr. Jibran Sharif will become the Chief Medical Officer of Datametrex.

Read More: https://agoracom.com/ir/DatametrexAI/forums/discussion/topics/755157-datametrex-announces-closing-of-acquisition-with-concierge-medical/messages/2303196#message

Tags: , , , , , , ,
Posted in Datametrex AI Limited | Comments Off on Datametrex $DM.ca $DTMXF Announces Closing of Acquisition with Concierge Medical $WELL.ca $DOC.ca $DOCRF $VMD.ca

Novamind $NM.ca Announces Strategic Investment in #Bionomics $BNOEF to Support #PTSD Clinical Trial $RVV.ca $MMED $PSYC.ca $FTRP.ca $CMPS $NUMI.ca

Posted by AGORACOM-JC at 8:20 AM on Thursday, February 11th, 2021

Cedar Clinical Research to be Evaluated to Support Phase IIb Trial of Novel PTSD Treatment

  • Announced that it has made a strategic investment of AU$827,486 (approximately CAN$810,000, the “Strategic Investment”), in Bionomics Limited (“Bionomics”) (ASX:BNO)(OTCQB:BNOEF) (Germany:AU000000BNO5), a biopharmaceutical company dedicated to developing better treatments for central nervous system disorders.
  • In addition, Cedar Clinical Research (“CCR”), a wholly owned subsidiary of Novamind based in Springville, Utah, will be evaluated by Bionomics as a clinical research site to conduct Bionomics’ Phase IIb trial examining BNC210.
  • BNC210 has received Fast Track Designation from the U.S. Food and Drug Administration for the treatment of post-traumatic stress disorder (PTSD).

TORONTO, ON / February 11, 2021 / Novamind Inc. (CSE:NM) (“Novamind”), a leading mental health company specialized in psychedelic medicine, is pleased to announce that it has made a strategic investment of AU$827,486 (approximately CAN$810,000, the “Strategic Investment”), in Bionomics Limited (“Bionomics”) (ASX:BNO)(OTCQB:BNOEF) (Germany:AU000000BNO5), a biopharmaceutical company dedicated to developing better treatments for central nervous system disorders.

In addition, Cedar Clinical Research (“CCR”), a wholly owned subsidiary of Novamind based in Springville, Utah, will be evaluated by Bionomics as a clinical research site to conduct Bionomics’ Phase IIb trial examining BNC210. BNC210 has received Fast Track Designation from the U.S. Food and Drug Administration for the treatment of post-traumatic stress disorder (PTSD).

With its investment in Bionomics, Novamind joins a group of well-known investors that specialize in psychedelics and biotech: Apeiron Investments, Biotech Value Fund, Merck & Co., Mike Novogratz, and Peter Thiel, an early investor in ATAI Life Sciences.

Novamind’s Strategic Investment is included in Bionomics’ latest round of financing, which was underwritten by Apeiron Investments and received commitments for AU$16,000,000 (approximately CAN$15,680,000, the “Bionomics Financing”). Novamind will purchase a total of 5,706,800 common shares in the Bionomics Financing, at AU$0.145 per share, a 20% discount to the 30-day volume weighted average price as of February 5th, 2021. Proceeds from the Bionomics Financing will support the initiation of a Phase IIb trial for BNC210, planned for mid-2021.

Bionomics intends to evaluate Cedar Clinical Research’s deep expertise in facilitating Phase I to Phase IV clinical trials for leading pharmaceutical companies, and how it may potentially serve as a research site for Bionomics’ Phase IIb clinical trial examining BNC210 in PTSD patients.

Cedar Clinical Research, led by Novamind’s Chief Medical Officer, Dr. Reid Robison, is currently contracted for seven clinical trials with various sponsors, including leading pharmaceutical companies. Dr. Robison has led over 100 clinical trials in neuropsychiatry, researching a spectrum of psychiatric conditions, including PTSD.

“I’m happy to welcome Novamind as a strategic investor in Bionomics,” said Dr. Errol De Souza, Executive Chairman of Bionomics. “Dr. Robison and the team at Cedar Clinical Research have unique experience related to clinical trials for mental health therapeutics.”

Yaron Conforti, CEO and Director of Novamind, added, “We are pleased to participate in Bionomics’ financing to support the development of its novel drug candidate for the treatment of PTSD. Cedar Clinical Research has unique expertise in PTSD research, and we look forward to the opportunity to contribute to the development of BNC210.”

To learn more about Cedar Clinical Research, please visit cedarclinicalresearch.com.

About Bionomics

Bionomics is a global, clinical stage biopharmaceutical company leveraging its proprietary platform technologies to discover and develop a deep pipeline of best in class, novel drug candidates. Bionomics’ lead drug candidate BNC210, currently in development for initiation of a second Phase II trial for the treatment of PTSD, is a novel, proprietary negative allosteric modulator of the alpha-7 (α7) nicotinic acetylcholine receptor. Beyond BNC210, Bionomics has a strategic partnership with Merck & Co., Inc (known as MSD outside the United States and Canada). To learn more, please visit bionomics.com.au.

About Novamind

Novamind is a leading mental health company enabling safe access to psychedelic medicine through a network of clinics, retreats, and clinical research sites. Novamind provides ketamine-assisted psychotherapy and other novel treatments through its network of Cedar Psychiatry clinics and operates Cedar Clinical Research, a contract research organization specialized in clinical trials and evidence-based research for psychedelic medicine. Both Cedar Psychiatry and Cedar Clinical Research are wholly owned subsidiaries of Novamind. For more information on how Novamind is enhancing mental wellness and guiding people through their entire healing journey, visit novamind.ca.

Contact Information

Novamind
Yaron Conforti, CEO and Director
Telephone: +1 (647) 953 9512
Bill Mitoulas, Investor Relations
Email: [email protected]

Forward-Looking Statements

This news release contains forward-looking statements. All statements other than statements of historical fact included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations including the risks detailed from time to time in the Company’s public disclosure. The reader is cautioned not to place undue reliance on any forward-looking information. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable laws.

SOURCE: Novamind Inc.

Read More: https://agoracom.com/ir/Novamind/forums/discussion/topics/755165-novamind-announces-strategic-investment-in-bionomics-to-support-ptsd-clinical-trial/messages/2303206#message

Tags: , , , , , , , ,
Posted in Featured, Novamind Inc. | Comments Off on Novamind $NM.ca Announces Strategic Investment in #Bionomics $BNOEF to Support #PTSD Clinical Trial $RVV.ca $MMED $PSYC.ca $FTRP.ca $CMPS $NUMI.ca

VIDEO – @goplantx $VEGA $PLTXF Reports Record Revenue of Over $1M For Month of January $VERY.ca $MEAT.ca $EATS.ca $VEGN.ca

Posted by AGORACOM-JC at 6:33 PM on Wednesday, February 10th, 2021

The paradigm shifting, parabolic growth of plant based foods and a plant based life is unstoppable, with the plant-based food market alone expected to reach $74.2 billion by 2027.

PlantX Life (VEGA:CSE) (PLTXF:OTCQB) Is The One Stop Shop For Everything Plant Based + The  Digital Face of The Plant -Based Community   More than just lip service, $VEGA reported revenue of $1,089,502 for the month of January 2021.

$VEGA is just getting started, with a line up of plant based products and services that includes:

  • Plant Based Meal Delivery (20 meals)
  • Plant Based Snack Products
  • Plant Based Pet foods
  • Plant Based Restaurant Locator
  • Plant Based Recipes
  • Plant Based Essentials …. Like Chocolate (Essential?  You Bet)
  • And …… Plant Based …. PLANTS (It’s A BIG Business!)

From an operations point of view, VEGA is already in full swing and growing FAST

  • Already Operating In Canada
  • US Online Operations Kick Off With $USD 25M MIN of PlantX products YEAR 1
    • 6% Royalty Fee to PlantX on gross USA revenues
  • US Bricks & Mortar with San Diego flagship store opening soon.
  • £8 million Acquisition of Bloombox In The UK, generating millions in revenue
  • Closed $11.5M Non-Brokered Private Placement
  • ….. and  Application To List On NASDAQ

If you believe in the massive paradigm shift towards plant based foods and more, be sure to watch and share this great interview with PlantX Founder Sean Dollinger.

Tags: , , , , ,
Posted in AGORACOM Via Satellite, All Recent Posts, Plant-Based Food, PlantX Life Inc. | Comments Off on VIDEO – @goplantx $VEGA $PLTXF Reports Record Revenue of Over $1M For Month of January $VERY.ca $MEAT.ca $EATS.ca $VEGN.ca

PlantX $PLTXF $VEGA.ca Announces Record-Breaking Monthly Gross Revenue of $1,089,502 for January 2021 $VERY.ca $MEAT.ca $EATS.ca $VEGN.ca

Posted by AGORACOM-JC at 8:42 AM on Wednesday, February 10th, 2021
  • Achieved record monthly gross revenue of $1,089,502 for the month of January 2021

VANCOUVER, BC , Feb. 10, 2021 – PlantX Life Inc. (CSE: VEGA ) (Frankfurt: WNT1) (OTCQB: PLTXF) (” PlantX ” or the ” Company “) is pleased to announce that it achieved record monthly gross revenue of $1,089,502 for the month of January 2021 . Cost of Goods Sold were $751,356 for the same month.

For the month of December 2020 and during the highly dynamic holiday season, the Company achieved gross revenue of $1,029,883 . This was surpassed by January 2021’s revenue, which exceeded management’s expectations given that e-commerce sales were expected to be slower following the holiday season. This success during one of the slowest e-commerce periods of the year highlights the tremendous impact the Company continues to have in the plant-based marketplace. The Company’s growth continues to be driven by its marketing and branding efforts, as well as the Company’s innovative partnerships. The strong sales figures reflect PlantX’s values-driven approach to successfully meeting consumer demand.

“It is truly encouraging to achieve yet another incredible revenue milestone and to start the new year with such vigor and success,” said PlantX CEO Julia Frank . “There are many other colourful growth opportunities on the horizon, and we’re confident that our financial trajectory will reflect the remarkable and increasing value our Company brings to the plant-based industry.”

The financial results disclosed in this press release are management prepared and have not been audited or reviewed by the Company’s auditors. Unless otherwise indicated, all amounts are expressed in Canadian dollars.

About PlantX Life Inc.

As the digital face of the plant-based community, PlantX’s platform is the one-stop shop for everything plant-based. With its fast-growing category verticals, the Company offers customers across North America more than 10,000 plant-based products. In addition to offering meal and indoor plant deliveries, the Company currently has plans underway to expand its product lines to include cosmetics, clothing and its own water brand — but the business is not limited to an e-commerce platform. The Company uses its digital platform to build a community of likeminded consumers and, most importantly, provide education. Its successful enterprise is being built and fortified on partnerships with top nutritionists, chefs and brands. The Company eliminates the barriers to entry for anyone interested in living a plant-based lifestyle and thriving in a longer, healthier and happier life.

The Company website is http://investor.PlantX.com/ .

Forward-Looking Information

This press release contains “forward-looking information” within the meaning of applicable securities laws. All statements contained herein that are not clearly historical in nature may constitute forward-looking information. In some cases, forward-looking information can be identified by words or phrases such as “may,” “will,” “expect,” “likely,” “should,” “would,” “plan,” “anticipate,” “intend,” “potential,” “proposed,” “estimate,” “believe” or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions “may” or “will” happen, or by discussions of strategy. The forward-looking information contained herein includes, without limitation, the business and strategic plans of the Company.

By its nature, forward-looking information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate; that assumptions may not be correct; and that objectives, strategic goals and priorities will not be achieved. A variety of factors, including known and unknown risks, many of which are beyond our control, could cause actual results to differ materially from the forward-looking information in this press release including, without limitation: the Company’s ability to comply with all applicable governmental regulations, including all applicable food safety laws and regulations; impacts to the business and operations of the Company due to the COVID-19 epidemic; a limited operating history; the ability of the Company to access capital to meet future financing needs; the Company’s reliance on management and key personnel; competition; changes in consumer trends; foreign currency fluctuations; and general economic, market or business conditions.

Additional risk factors can also be found in the Company’s continuous disclosure documents, which have been filed on SEDAR and can be accessed at www.sedar.com . Readers are cautioned to consider these and other factors, uncertainties and potential events carefully and not to put undue reliance on forward-looking information. The forward-looking information contained herein is made as of the date of this press release and is based on the beliefs, estimates, expectations and opinions of management on the date such forward-looking information is made. The Company undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law.

Read More: https://agoracom.com/ir/PlantX/forums/discussion/topics/755080-plantx-announces-record-breaking-monthly-gross-revenue-of-1-089-502-for-january-2021/messages/2303027#message

Tags: , , , , , ,
Posted in PlantX Life Inc. | Comments Off on PlantX $PLTXF $VEGA.ca Announces Record-Breaking Monthly Gross Revenue of $1,089,502 for January 2021 $VERY.ca $MEAT.ca $EATS.ca $VEGN.ca

Peak $PKK.ca $PKKFF Successfully Tests Fund Transfer Process from China to Canada $MOS.ca $MOGO.ca CTZ.ca $TRAD.ca

Posted by AGORACOM-JC at 8:25 AM on Wednesday, February 10th, 2021
Peak Fintech Group (@PEAK_Fintech) | Twitter
  • Announced that it has successfully tested the process whereby the its Chinese operating subsidiaries will periodically send funds back to Canada once the Company becomes profitable and deems it appropriate for its subsidiaries to do so.
  • “Today’s announcement has been several years in the making,” commented Peak CEO Johnson Joseph. “We’ve been following our advisors’ advice from day one and were always confident that the process would work as described.

Montreal, Quebec–(February 10, 2021) – Peak Fintech Group Inc. (CSE: PKK) (OTCQX: PKKFF) (“Peak” or the “Company”), an innovative Fintech service provider to the Chinese commercial lending sector, today announced that it has successfully tested the process whereby the its Chinese operating subsidiaries will periodically send funds back to Canada once the Company becomes profitable and deems it appropriate for its subsidiaries to do so.

Long before establishing its operating subsidiaries in China, Peak worked with business consultants, tax experts, legal and financial advisors specialized in helping foreign entities do business in China. Together they helped Peak create and put in place a corporate structure and file the necessary paperwork so that Peak’s subsidiaries could eventually follow a government-established process to send funds to the Company’s Canadian head office. Part of the exercise required a disclosure process with various government departments at the time of registration and creation of each subsidiary, and the continuous maintenance in good standing of prescribed regulations, all of which led to the first successful transfer of funds from Peak’s Asia Synergy Data Solutions subsidiary to the Company.

“Today’s announcement has been several years in the making,” commented Peak CEO Johnson Joseph. “We’ve been following our advisors’ advice from day one and were always confident that the process would work as described. But until recently we weren’t in a position to test it or had real grounds to do so. However, given the path that the Company is currently on and the possibility of repatriating funds from China at some point in 2021, we felt it was important for us to test the process to ensure that it actually works. We have now validated that we have a clear path and process, endorsed and prescribed by the Chinese government authorities, for our subsidiaries to send funds from China to Canada. We’re also very pleased with the amount we were able to transfer and how quickly the transaction was completed.”

Read more: https://agoracom.com/ir/PeakFintechGroup/forums/discussion/topics/755074-peak-successfully-tests-fund-transfer-process-from-china-to-canada/messages/2303017#message

Tags: , , , , , ,
Posted in Peak Fintech Group | Comments Off on Peak $PKK.ca $PKKFF Successfully Tests Fund Transfer Process from China to Canada $MOS.ca $MOGO.ca CTZ.ca $TRAD.ca

FansUnite $FANS.ca $FUNFF Signs Engagement Letter with Gaming Law Firm to Pursue U.S. Licensing Strategy $SCR.ca $BRAG.ca $TNA.ca $FDM.ca $JJ.ca

Posted by AGORACOM-JC at 8:12 AM on Wednesday, February 10th, 2021

  • Announced that the Company engaged the services of Ifrah Law PLLC, a prominent U.S. gaming law firm to collaborate with OneComply Inc. in assisting FansUnite with their U.S. licensing strategy.
  • Ifrah Law will guide FansUnite in navigating multiple state licenses in 2021, starting with New Jersey

Vancouver, British Columbia–(February 10, 2021) – FansUnite Entertainment Inc. (CSE: FANS) (OTCQB: FUNFF) (“FansUnite” or the “Company”) is pleased to announce that the Company engaged the services of Ifrah Law PLLC (“Ifrah Law”), a prominent U.S. gaming law firm to collaborate with OneComply Inc. (“OneComply”) in assisting FansUnite with their U.S. licensing strategy.

In response to the interest that FansUnite has received from U.S. gambling and casino operators for their sports betting and iGaming solutions, a founding member of Ifrah Law, Jeff Ifrah, will provide counsel to FansUnite on their rapid expansion strategy across the different U.S. jurisdictions beginning with New Jersey.

Jeff is an accomplished lawyer who is nationally ranked by Chambers USA in Gaming & Licensing Law given his reputation for legal excellence as well as his involvement with major prosecutions and lawsuits in the North American iGaming industry. Jeff’s expertise and extensive experience in the U.S. gaming landscape will be integral to FansUnite’s growth in the U.S. online gambling market as the Company seeks to acquire multiple state licenses in 2021, starting with the gaming license of New Jersey. In addition, Jeff has worked with OneComply on numerous occasions and therefore, his contribution will bolster OneComply’s efforts in streamlining the legal process for FansUnite’s entry into the U.S.

“Jeff and his team are a great addition to the global legal team that we have assembled to oversee the delivery of FansUnite’s offerings,” said Scott Burton, CEO of FansUnite. “With a long-standing career as a prominent attorney in gaming law, Jeff will accelerate our expansion into the highly complex U.S. betting and iGaming market.”

Read More: https://agoracom.com/ir/FansUniteEntertainment/forums/discussion/topics/755073-fansunite-signs-engagement-letter-with-gaming-law-firm-to-pursue-u-s-licensing-strategy/messages/2303016#message

Tags: , , , , , ,
Posted in FansUnite Entertainment Inc. | Comments Off on FansUnite $FANS.ca $FUNFF Signs Engagement Letter with Gaming Law Firm to Pursue U.S. Licensing Strategy $SCR.ca $BRAG.ca $TNA.ca $FDM.ca $JJ.ca

Empower Clinics $CBDT.ca $EPWCF Secures Medical Device Establishment Licence (MDEL) Status To Sell KAI Saliva COVID-19 PCR Test Kits In Canada $WELL.ca $DOC.ca $DOCRF $VMD.ca

Posted by AGORACOM-JC at 8:05 AM on Wednesday, February 10th, 2021
  • Announced it has secured Medical Device Establishment Licence (“MDEL”) status to sell its KAI Medical COVID-19 Saliva Test kits (“KAI Saliva”).
  • KAI Saliva is FDA EUA approved for use, has CE Mark and the saliva specimen collection device is approved by Health Canada.
  • KAI Saliva provides travellers, both foreign and domestic with a simple, fully compliant method to obtain an RT-PCR test and test result prior to arriving or coming back into to Canada or arriving to other countries that have similar executive travel orders.

VANCOUVER BC / February 10, 2021 / EMPOWER CLINICS INC. (CBDT:CSE) (8EC:Frankfurt) (EPWCF:OTCQB) (“Empower” or the “Company“) an integrated healthcare company serving patients through medical centres, telemedicine platforms, operating a high complexity medical diagnostics laboratory processing thousands of COVID-19 specimens, is pleased to announce it has secured Medical Device Establishment Licence (“MDEL”) status to sell its KAI Medical COVID-19 Saliva Test kits (“KAI Saliva”).

KAI Saliva is FDA EUA approved for use, has CE Mark and the saliva specimen collection device is approved by Health Canada. KAI Saliva provides travellers, both foreign and domestic with a simple, fully compliant method to obtain an RT-PCR test and test result prior to arriving or coming back into to Canada or arriving to other countries that have similar executive travel orders.

EMPOWER ACCELERATES ABILITY TO DISTRIBUTE AND SELL MEDICAL DEVICE PRODUCTS IN CANADA THROUGH PARTNERSHIP WITH MEDIPRO CANADA

Empower previously announced the filing of an MDEL application for the purpose of importing, distributing and selling KAI Saliva, which has experienced success upon its launch.

To accelerate the process, Empower partnered with MediPro Canada Inc. (“MediPro”) to utilize their approved MDEL status. MediPro provides healthcare products for governments, large corporations and medical facilities around the world and is led by Hon. Sheila Maureen Copps PC OC.

“We continue to see extensive demand for novel COVID-19 testing products in both private sector and public sector markets throughout North America, Mexico and Caribbean countries.” said Hon. Sheila Copps OC, Partner MediPro Canada. “Leveraging the vast network of MediPro Canada with the integrated healthcare capabilities of Empower Clinics and their novel COVID-19 testing products, makes for an ideal partnership.”

“We all have an urgent requirement for a home-based, self-administered COVID-19 saliva test kit that can help open up the economy and facilitate travel that meets the requirements of the executive travel orders.” said Steven McAuley, Chairman & CEO. “We also must utilize our resources, our reach, our capability, do everything we can to assist, be humanitarians, use our voice, strive to provide improved healthcare, and lead the path of progressive healthcare.”

Read More: https://agoracom.com/ir/EmpowerClinics/forums/discussion/topics/755072-empower-clinics-secures-medical-device-establishment-licence-mdel-status-to-sell-kai-saliva-covid-19-pcr-test-kits-in-canada/messages/2303015#message

Tags: , , , , ,
Posted in Empower Clinics Inc. | Comments Off on Empower Clinics $CBDT.ca $EPWCF Secures Medical Device Establishment Licence (MDEL) Status To Sell KAI Saliva COVID-19 PCR Test Kits In Canada $WELL.ca $DOC.ca $DOCRF $VMD.ca

ImagineAR $IP.ca $IPNFF Announces Blue United Corporation as its Official Agency for Japan Expansion $DBO.ca $YDX.ca $SEV.ca $NTAR.ca

Posted by AGORACOM-JC at 8:00 AM on Wednesday, February 10th, 2021
http://www.smallcapepicenter.com/imagine%20ar%20squre.jpg
  • Announced a partnership with Blue United Corporation as its official agency to launch the ImagineAR Augmented Reality Platform in Japan
  • Blue United clients include Kashima Antlers, Matsumoto Yamaga , Yanmar, Under Armour, Omiya Ardija and the Pacific League Marketing (holding that represents the commercial interests of 6 teams of the Japanese Baseball League) and Sevilla FC, among others.

VANCOUVER, BC, Feb. 10, 2021 – ImagineAR (CSE: IP) (OTCQB: IPNFF) an Augmented Reality Company that enables sports teams, brands and businesses to instantly create mobile phone AR campaigns, is pleased to announce a partnership with Blue United Corporation as its official agency to launch the ImagineAR Augmented Reality Platform in Japan.  Blue United clients include Kashima Antlers, Matsumoto Yamaga , Yanmar, Under Armour, Omiya Ardija and the Pacific League Marketing (holding that represents the commercial interests of 6 teams of the Japanese Baseball League) and Sevilla FC, among others.

Blue United Corporation is a marketing, PR, and business development agency with offices in New York , Tokyo and Nagano . With a vast experience in International expansion and business development, Blue United Corporation, focuses on elevating brands on a global scale and help them on expanding internationally (business development and expansion, PR/Communications, social media, marketing, etc.), owns and manages the only football professional tournament between club teams that are part of the Pacific Rim Region (Pacific Rim Cup), and is the owner of esports Blue United eFC, current Asian champion of FIFA.

ImagineAR believes Blue United’s experience will significantly accelerate the Company’s presence and sales throughout Japan , a strategic new market for ImagineAR.

Takehiko Nakamura , CEO of Blue United, said; “ImagineAR is the most advanced sports fan engagement Augmented Reality platform in the global market today and we are excited to assist the company to launch its sales and marketing initiatives in Japan . Sports teams can drive new fan engagement and brand activation using ImagineAR and the Japan sports market requires this type of advanced immersive mobile experiential platform to drive new revenue streams.”

Read More: https://agoracom.com/ir/Imaginear/forums/discussion/topics/755071-imaginear-otcqb-ipnff-announces-blue-united-corporation-as-its-official-agency-for-japan-expansion/messages/2303014#message

Tags: , , , , , , ,
Posted in Imagine AR | Comments Off on ImagineAR $IP.ca $IPNFF Announces Blue United Corporation as its Official Agency for Japan Expansion $DBO.ca $YDX.ca $SEV.ca $NTAR.ca

VIDEO – PyroGenesis $PYR.ca Goes Live For Q&A With Shareholders As Market Cap Surpasses $1 BILLION

Posted by AGORACOM-JC at 6:02 PM on Tuesday, February 9th, 2021

To say that PyroGenesis Canada (PYR:TSX) and its CEO, Peter Pascali, share a mutual love and respect with shareholders unlike anything we have ever seen is not an overstatement.  

This is a group (Company, CEO and Shareholders) that have been through the highs and lows of PyroGenesis over the years TOGETHER.  That bond only got tighter when Pascali took to the PYR Verified Forum on AGORACOM to speak with investors directly and openly with his first ever post on June 21, 2017 followed by more than 20 in-depth videos in which he took his engagement with investors even deeper by answering every single question possible to the best of his ability.  

Knowing this, it should not surprise anybody learning about PyroGenesis for the first time that shareholders have coined the rallying call of “In Peter We Trust”.  

Today PyroGenesis, Pascali and shareholders shared another major milestone together in a live Q&A that coincided with PyroGenesis surpassing a $1 BILLION MARKET CAP.  It was an incredibly special event that could not be made clearer than by many of the questions and comments that referred not just to the Company’s bottom – but to its soul and philosophy.    

I’ve never seen it before.  All I can say is that it is a thrill to be witness to and part of something this deeply special in an industry that rarely looks beyond the next quarter.  

Congratulations to Peter, the Pyro team and this incredible group of shareholders.  

George and the AGORACOM team.  

Watch, listen and enjoy today’s interview with CEO Peter Pascali.

Tags: , , , , ,
Posted in AGORACOM Via Satellite, Featured, PyroGenesis Canada Inc. | Comments Off on VIDEO – PyroGenesis $PYR.ca Goes Live For Q&A With Shareholders As Market Cap Surpasses $1 BILLION

Empower $CBDT.ca $EPWCF Partners with #Rexall $MCK To Launch Integrated Healthcare Centres $WELL.ca $DOC.ca $DOCRF $VMD.ca

Posted by AGORACOM-JC at 12:26 PM on Tuesday, February 9th, 2021

Partnership Accelerates Empower’s Strategy To Execute National Healthcare Centre Expansion By Bringing Accessible and Progressive Primary Care and Para-Medical Care to Millions of Canadians

  • Announced effective February 8, 2021 a partnership with Rexall Pharmacy Group to launch the first of multiple integrated healthcare centres within Rexall pharmacies commencing in Ontario, Canada.
  • Empower will be opening primary care, plus para-medical healthcare services in each of the locations, with a target of four (4) to six (6) Medical Doctors (MD) and four (4) to six (6) paramedical practitioners per location.

VANCOUVER, BC / February 9, 2021 / EMPOWER CLINICS INC. (CSE:CBDT)(Frankfurt:8EC)(OTCQB:EPWCF) (“Empower” or the “Company“) an integrated healthcare company serving patients through medical centres, telemedicine platforms, operating a high complexity medical diagnostics laboratory processing thousands of COVID-19 specimens, is pleased to announce effective February 8, 2021 a partnership with Rexall Pharmacy Group to launch the first of multiple integrated healthcare centres within Rexall pharmacies commencing in Ontario, Canada.

“In our first press release of 2021 announcing the closing of our Canadian Clinics acquisition, I stated Empower had a winning business model with immediate expansion plans throughout Greater Toronto, followed by Ontario and then nationwide with at least 30 clinics in rapid succession. Empower is proud to begin delivering on that promise.” said Steven McAuley, Chairman & CEO. “To say this is the Company’s biggest announcement in its history would not be an over statement. This partnership with Rexall accelerates our nationwide healthcare expansion strategy, I look forward to bringing Six Sigma philosophies and continuous process improvements to our operations to ensure customers and our patients have access to our primary care and para-medical services for years to come. Today marks a major win for Canadian healthcare and the shareholders of Empower Clinics.”

PARTNERSHIP IDENTIFIES INITIAL LOCATIONS IN ONTARIO

Rexall and Empower have identified numerous initial locations throughout Ontario, spanning from Ottawa to London and around the GTA. The size of the locations can range from 1,500 to 4,000 square feet. As each new location is agreed upon, key terms are outlined in a letter of intent and in the lease or sub-lease agreements with the first anticipated agreements February 2021.

HEALTH CARE SERVICES TO BE DELIVERED

Empower will be opening primary care, plus para-medical healthcare services in each of the locations, with a target of four (4) to six (6) Medical Doctors (MD) and four (4) to six (6) paramedical practitioners per location.

Primary care services include:

  • Family physicians
  • Walk-in physicians
  • Tele-medicine and virtual care

Paramedical services include:

  • Chiropractic
  • Physiotherapy
  • Registered Massage Therapy
  • Chiropody
  • Acupuncturists
  • Osteopaths
  • Nutritionists

ADDITIONAL HEALTH CARE SERVICES EXPECTED TO BE ADDED

Given the anticipated expansion and penetration of Empower Clinics into the Canadian market, the Company intends to continue adding valuable specialized medical services to strengthen the quality of healthcare at each location that can include:

  • Dermatology
  • Cardiology

Read More: https://agoracom.com/ir/EmpowerClinics/forums/discussion/topics/754999-empower-partners-with-rexall-r-to-launch-integrated-healthcare-centres/messages/2302856#message

Tags: , , , , , ,
Posted in Empower Clinics Inc. | Comments Off on Empower $CBDT.ca $EPWCF Partners with #Rexall $MCK To Launch Integrated Healthcare Centres $WELL.ca $DOC.ca $DOCRF $VMD.ca

« Older Entries
Newer Entries »